Towards a new combination therapy for tuberculosis with next generation benzothiazinones

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

Abstract The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo‐enzyme DprE1, decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase. Here, we synthesized a new series of piperazine‐containing benzothiazinones (PBTZ) and show that, like BTZ043, the prec...

Full description

Bibliographic Details
Main Authors: Vadim Makarov, Benoit Lechartier, Ming Zhang, João Neres, Astrid M van der Sar, Susanne A Raadsen, Ruben C Hartkoorn, Olga B Ryabova, Anthony Vocat, Laurent A Decosterd, Nicolas Widmer, Thierry Buclin, Wilbert Bitter, Koen Andries, Florence Pojer, Paul J Dyson, Stewart T Cole
Format: Article
Language:English
Published: Springer Nature 2014-02-01
Series:EMBO Molecular Medicine
Subjects:
benzothiazinones
combination regimens
DprE1
tuberculosis
Online Access:https://doi.org/10.1002/emmm.201303575

Internet

https://doi.org/10.1002/emmm.201303575

Similar Items